|
시장보고서
상품코드
1673016
PD-1 및 PD-L1 억제제 시장 : 억제제 유형별, 암 유형별, 유통 채널별, 지역별PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, By Cancer Type, By Distribution Channel, By Geography |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
세계의 PD-1 및 PD-L1 억제제 시장은 2025년 622억 3,000만 달러, 2032년에는 2,043억 1,000만 달러에 달할 것으로 예측되며, 2025-2032년 CAGR 18.5%로 성장할 것으로 예상됩니다.
| 보고 범위 | 보고서 상세 내용 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 622억 3,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간(2025-2032년) CAGR | 18.50% | 2032년 금액 예측 | 2,043억 1,000만 달러 |
그림. PD-1 및 PD-L1 억제제 시장 점유율(%), 2025년 지역별
PD-1 및 PD-L1 억제제는 면역관문억제제이며, 암 치료에서 유망한 결과를 보여주고 있습니다. 체크포인트 억제제는 PD-1과 PD-L1이라는 단백질을 차단하여 종양이 면역체계의 공격을 피하도록 도와주는 PD-1과 PD-L1이라는 단백질을 차단함으로써 신체의 자연적 항종양 반응을 향상시키는 데 도움을 줍니다. PD-1과 PD-L1 억제제는 최근 흑색종, 폐암 등 다양한 암에 대한 사용이 승인되었으며, 기존 치료법보다 임상 결과가 개선되어 기존 치료법보다 더 나은 임상 결과를 얻을 수 있습니다. 기존 치료법에 비해 개선된 임상 결과로 인해 이들 억제제 시장은 크게 성장하고 있으며, 향후 몇 년동안 높은 성장이 예상됩니다.
시장 역학
PD-1 및 PD-L1 억제제 세계 시장 성장의 원동력은 전 세계 암 발병률 증가와 유망한 임상적 효능으로 인한 면역관문억제제의 임상적 채택 증가입니다. 또한, 새로운 PD-1 및 PD-L1 억제제가 암 적응증으로 승인 및 출시되면서 시장 성장을 더욱 촉진하고 있습니다. 그러나 이들 약물의 개발 및 제조에 소요되는 높은 비용과 고가의 가격 설정으로 인한 시장 성장 억제요인도 있어 보급에 한계가 있습니다. 체크포인트 억제제와 다른 항암제와의 병용요법 가능성을 평가하기 위한 임상시험이 진행 중이며, 장기적으로 시장 진출기업에게 유리한 기회가 될 수 있습니다.
본 조사의 주요 특징
- 세계의 PD-1 및 PD-L1 억제제 시장을 상세하게 분석하여 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 본 보고서에서는 세계 PD-1 및 PD-L1 억제제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등의 파라미터를 기반으로 정리하여 수록했습니다.
- 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- PD-1 및 PD-L1 억제제 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 PD-1 및 PD-L1 억제제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차 :
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
- Coherent Opportunity Map (COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 암 발생률/유병률 상승
- 암치료 고액의 비용
- 연구개발 활동 증가
- 영향 분석
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- Porter's Five Forces 분석
- 인수합병(M&A) 시나리오
제4장 세계의 PD-1 및 PD-L1 억제제 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급측과 수요측 분석
- 경제에 대한 영향
제5장 세계의 PD-1 및 PD-L1 억제제 시장, 억제제 유형별, 2020-2032년
- 서론
- PD-1 억제제
- PD-L1억제제
제6장 세계의 PD-1 및 PD-L1 억제제 시장, 암 유형별, 2020-2032년
- 서론
- 신장
- 악성 흑색종
- 방광
- 비소세포 폐암
- 간
- 두경부
- 기타
제7장 세계의 PD-1 및 PD-L1 억제제 시장, 유통 채널별, 2020-2032년
- 서론
- 병원 약국
- 소매 약국
- 온라인 약국
제8장 세계의 PD-1 및 PD-L1 억제제 시장, 지역별, 2020-2032년
- 서론
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제9장 경쟁 구도
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
제10장 애널리스트의 견해
- 융성과 쇠퇴
- Coherent Opportunity Map
제11장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
Global PD-1 and PD-L1 Inhibitor Market is estimated to be valued at USD 62.23 Bn in 2025 and is expected to reach USD 204.31 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.5% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 62.23 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 18.50% | 2032 Value Projection: | USD 204.31 Bn |
Figure. PD-1 And PD-L1 Inhibitor Market Share (%), By Region 2025
PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors that have shown promising results in cancer treatment. Checkpoint inhibitors help boost the body's natural anti-tumor response by blocking proteins called PD-1 and PD-L1 that help tumors evade immune system attacks. By blocking these proteins, checkpoint inhibitors allow the immune system cells called T cells to recognize and attack cancer cells more effectively. Several PD-1 and PD-L1 inhibitors have been approved in recent years for use against various cancers like melanoma, lung cancer and more. With their improved clinical outcomes compared to conventional therapies, the market for these inhibitors has grown substantially and is expected to witness high growth in the coming years.
Market Dynamics:
The global PD-1 and PD-L1 inhibitor market growth is driven by the rising prevalence of cancer worldwide and the increasing adoption of immune checkpoint inhibitors in clinical practice due to their promising clinical efficacy. Moreover, the approval and launch of new PD-1 and PD-L1 inhibitors for additional cancer indications is further fueling the market growth. However, the market faces restraints from the high costs associated with developing and manufacturing these drugs as well as their expensive pricing which limits widespread adoption. Ongoing clinical trials evaluating the potential of combining checkpoint inhibitors with other anticancer therapies presents lucrative opportunities for market players in the long run.
Key Features of the Study:
- This report provides an in-depth analysis of the global PD-1 and PD-L1 inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global PD-1 and PD-L1 inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Merck & Co., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, and BeiGene LTD.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global PD-1 and PD-L1 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PD-1 and PD-L1 inhibitor market.
Market Segmentation
- Type of Inhibitor:
- PD-1 Inhibitors
- PD-L1 Inhibitors
- Cancer Type:
- Kidney
- Melanoma
- Bladder
- Non-small Cell Lung Cancer
- Liver
- Head & neck
- Others
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- Merck & Co.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type of Inhibitor
- Market Snapshot, By Cancer Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in incidence/prevalence of cancer
- High cost of cancer treatment
- Rise in research and development activities
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global PD-1 and PD-L1 Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- PD-1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- PD-L1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global PD-1 and PD-L1 Inhibitor Market, By Cancer Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Kidney
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Bladder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Non-small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Liver
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Head & Neck
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global PD-1 and PD-L1 Inhibitor Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global PD-1 and PD-L1 Inhibitor Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
샘플 요청 목록